Compass Therapeutics (CMPX) Expected to Announce Earnings on Thursday

Compass Therapeutics (NASDAQ:CMPX) will likely be releasing its earnings data before the market opens on Thursday, March 20th. Analysts expect Compass Therapeutics to post earnings of ($0.10) per share for the quarter.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Stock Down 4.5 %

Shares of CMPX opened at $2.35 on Tuesday. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $4.08. The firm’s fifty day moving average is $2.82 and its two-hundred day moving average is $2.06. The stock has a market cap of $324.97 million, a PE ratio of -6.35 and a beta of 1.19.

Analyst Upgrades and Downgrades

A number of research firms have commented on CMPX. Jefferies Financial Group upped their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. D. Boral Capital reiterated a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research note on Tuesday, February 25th. Guggenheim started coverage on shares of Compass Therapeutics in a research note on Monday, February 24th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Piper Sandler started coverage on shares of Compass Therapeutics in a research note on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price on the stock. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.38.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.